Shandong Boan Biotechnology Co Ltd
HKEX:6955
Intrinsic Value
Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. [ Read More ]
The intrinsic value of one Shandong Boan Biotechnology Co Ltd stock under the Base Case scenario is 18.57 HKD. Compared to the current market price of 9.8 HKD, Shandong Boan Biotechnology Co Ltd is Undervalued by 47%.
Valuation Backtest
Shandong Boan Biotechnology Co Ltd
Run backtest to discover the historical profit from buying and selling Shandong Boan Biotechnology Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Balance Sheet Decomposition
Shandong Boan Biotechnology Co Ltd
| Current Assets | 713m |
| Cash & Short-Term Investments | 201.9m |
| Receivables | 276.2m |
| Other Current Assets | 235m |
| Non-Current Assets | 1.6B |
| PP&E | 659.9m |
| Intangibles | 950.5m |
| Current Liabilities | 653.3m |
| Accounts Payable | 185.7m |
| Short-Term Debt | 31.9m |
| Other Current Liabilities | 435.8m |
| Non-Current Liabilities | 350.2m |
| Long-Term Debt | 234.5m |
| Other Non-Current Liabilities | 115.7m |
Earnings Waterfall
Shandong Boan Biotechnology Co Ltd
|
Revenue
|
618.1m
CNY
|
|
Cost of Revenue
|
-209.2m
CNY
|
|
Gross Profit
|
409m
CNY
|
|
Operating Expenses
|
-515.4m
CNY
|
|
Operating Income
|
-106.4m
CNY
|
|
Other Expenses
|
-12.9m
CNY
|
|
Net Income
|
-119.4m
CNY
|
Free Cash Flow Analysis
Shandong Boan Biotechnology Co Ltd
| CNY | |
| Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Shandong Boan Biotechnology Co Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Shandong Boan Biotechnology Co Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shandong Boan Biotechnology Co Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Shandong Boan Biotechnology Co Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shandong Boan Biotechnology Co Ltd
According to Wall Street analysts, the average 1-year price target for Shandong Boan Biotechnology Co Ltd is 10.65 HKD with a low forecast of 10.54 HKD and a high forecast of 10.96 HKD.
Shareholder Return
Price
Shandong Boan Biotechnology Co Ltd
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -62% |
| Market Capitalization | 5B HKD |
| Shares Outstanding | 509 278 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Shandong Boan Biotechnology Co Ltd stock under the Base Case scenario is 18.57 HKD.
Compared to the current market price of 9.8 HKD, Shandong Boan Biotechnology Co Ltd is Undervalued by 47%.
You don't have any saved screeners yet
